JP2018535647A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535647A5
JP2018535647A5 JP2018513423A JP2018513423A JP2018535647A5 JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5 JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
ile
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513423A
Other languages
English (en)
Japanese (ja)
Other versions
JP7185524B2 (ja
JP2018535647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050875 external-priority patent/WO2017048593A1/en
Publication of JP2018535647A publication Critical patent/JP2018535647A/ja
Publication of JP2018535647A5 publication Critical patent/JP2018535647A5/ja
Priority to JP2022188263A priority Critical patent/JP7461445B2/ja
Application granted granted Critical
Publication of JP7185524B2 publication Critical patent/JP7185524B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513423A 2015-09-15 2016-09-09 Hla-cw8拘束性の変異krasを認識するt細胞受容体 Active JP7185524B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188263A JP7461445B2 (ja) 2015-09-15 2022-11-25 Hla-cw8拘束性の変異krasを認識するt細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188263A Division JP7461445B2 (ja) 2015-09-15 2022-11-25 Hla-cw8拘束性の変異krasを認識するt細胞受容体

Publications (3)

Publication Number Publication Date
JP2018535647A JP2018535647A (ja) 2018-12-06
JP2018535647A5 true JP2018535647A5 (OSRAM) 2019-10-17
JP7185524B2 JP7185524B2 (ja) 2022-12-07

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018513423A Active JP7185524B2 (ja) 2015-09-15 2016-09-09 Hla-cw8拘束性の変異krasを認識するt細胞受容体
JP2022188263A Active JP7461445B2 (ja) 2015-09-15 2022-11-25 Hla-cw8拘束性の変異krasを認識するt細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188263A Active JP7461445B2 (ja) 2015-09-15 2022-11-25 Hla-cw8拘束性の変異krasを認識するt細胞受容体

Country Status (13)

Country Link
US (3) US10556940B2 (OSRAM)
EP (2) EP3901169A1 (OSRAM)
JP (2) JP7185524B2 (OSRAM)
KR (2) KR102841067B1 (OSRAM)
CN (2) CN108350059B (OSRAM)
AU (3) AU2016323017B2 (OSRAM)
DK (1) DK3350213T3 (OSRAM)
ES (1) ES2879287T3 (OSRAM)
IL (1) IL257840B2 (OSRAM)
MX (1) MX2018003062A (OSRAM)
SA (1) SA518391109B1 (OSRAM)
SG (1) SG10201913868XA (OSRAM)
WO (1) WO2017048593A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
AU2017306038B2 (en) 2016-08-02 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KRAS-G12D T cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3602053B1 (en) * 2017-03-31 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス,インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
EA202090652A1 (ru) * 2017-09-20 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
IL273698B2 (en) 2017-10-05 2025-07-01 Us Health Methods for selectively expanding cells expressing a tcr with a murine constant region
CN119162251A (zh) * 2017-12-04 2024-12-20 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
BR112021002826A2 (pt) * 2018-08-16 2021-05-04 Biontech Us Inc. construtos de receptor de célula t e usos dos mesmos
JP7672979B2 (ja) * 2019-01-22 2025-05-08 アメリカ合衆国 G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体
EP3927727A1 (en) 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN114175087A (zh) * 2019-08-14 2022-03-11 日本电气株式会社 信息处理装置、信息处理方法和记录介质
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ (ユーケイ) リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
CA3167382A1 (en) * 2020-02-14 2021-08-19 Steven A. Rosenberg Hla class i-restricted t cell receptors against ras with g12v mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
WO2022015922A1 (en) * 2020-07-16 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
EP4298121A1 (en) 2021-02-25 2024-01-03 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
CA2497552C (en) 2002-09-06 2014-05-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
PT2327763T (pt) * 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Geração de células t específicas de antigénios
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP3213765B1 (en) 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SI3392270T1 (sl) * 2011-09-15 2020-12-31 The United States Of America, As Represented By The Secretary Department Of Health And Human Services T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni MAGE
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
SI3223850T1 (sl) 2014-11-26 2020-09-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutiran kras T-celični receptorji

Similar Documents

Publication Publication Date Title
JP2018535647A5 (OSRAM)
IL273254B1 (en) Hla class ii–restricted t cell receptors against mutated ras
JP2017536825A5 (OSRAM)
FI3688027T3 (fi) Mutatoidun p53:n tunnistavia t-solureseptoreita
JP2015535816A5 (OSRAM)
JP2015525208A5 (OSRAM)
ES2984937T3 (es) Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
JP2020534828A5 (OSRAM)
JP2020511936A5 (OSRAM)
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
RS55822B1 (sr) Terapijski peptidi
EP4480967A1 (en) Development and use of novel immunomodulator
JP2016503295A5 (OSRAM)
JP2017524372A5 (OSRAM)
RU2018128215A (ru) Антитела против mica
KR20180016321A (ko) 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
JP2013502913A5 (OSRAM)
RU2016124670A (ru) Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
CN113527473A (zh) 一种全人源单克隆抗体及其应用
CN110194799A (zh) 结合犬pd-1的抗犬pd-1抗体
JP2017536821A5 (OSRAM)
CN112094348A (zh) 抗人Tim3抗体或其功能性片段及其应用
Zuo et al. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding
CA2967778A1 (en) Anti-thyroglobulin t cell receptors
CN108530538A (zh) EpCAM单域抗体E6